Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME ...

Anavex Life Sciences completed clinical studies (ADME and DDI) on blarcamesine, supporting its clinical pharmacology data package recommended by the FDA for Alzheimer's, Rett syndrome, and Fragile X syndrome programs. The FDA cleared its IND application for Fragile X syndrome, and a meeting is scheduled to discuss adding pediatric participants to the Rett syndrome Phase 3 trial.

This Wire brief sits within Fusion42's coverage of Biotech.